Clinical Trials in Austin

Showing 4621-4640 of 15,205 trials

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

NCT05032040

This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of vudalimab (XmAb20717) in patients with selected advanced gynecologic and genitourinary malignancies.

Ovarian CancerClear Cell CarcinomaEndometrial Cancer+2 more

Xencor, Inc.170 participantsStarted Jul 2022

Prescott, Arizona, United States • La Jolla, California, United States • Los Angeles, California, United States +14 more locations

COMPLETEDPhase 1< 1 mile

A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy Participants

NCT06497517

This study is a single center, single dose, open-label, randomly assigned 2-way crossover study. The study will investigate the food effect on the pharmacokinetics of Camlipixant (GSK5464714) in healthy male and female participants. Eligible participants will be randomized to pre-defined sequences. There will be a washout of minimum 7 days between each dose of treatment period.

Cough

Bellus Health Inc. - a GSK company14 participantsStarted Jul 2024

Austin, Texas, United States

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

A Study to Investigate the Effect of Food on Camlipixant Concentrations in Healthy Participants

Find Trials by Condition in Austin

Study on BI 54903 (Inhaled Corticosteroid) Administered Twice Daily Via Respimat Inhaler in Patients With Asthma Inadequately Controlled on Medium Dose Inhaled Corticosteroid (ICS).

A Phase 3 Study to Evaluate the Efficacy and Safety of TNX-102 SL in Participants With PTSD

A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-Traumatic Stress Disorder (PTSD)

Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis

This is a Study to Evaluate the Safety and Tolerability of ABL503, and to Determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of ABL503 in Subjects with Any Progressive Locally Advanced or Metastatic Solid Tumors

LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

A Study of Imvotamab in Severe Systemic Lupus Erythematosus

A Study of the Safety and Tolerability in Participants With PIK3CA-related Overgrowth Spectrum or Proteus Syndrome Who Are Being Treated With Miransertib (MK-7075) in Other Studies (MK-7075-006)

myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home

Framing Eighteen Coils in Cerebral Aneurysms Trial

Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements

Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy

Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children

Repigmentation of Stable Vitiligo Lesions Using Spray-On Skin™ Cells

A Clinical Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of PGDM1400LS Alone and in Combination With VRC07-523LS and PGT121.414.LS in Healthy, HIV-uninfected Adult Participants

Open-Label Study of Setmelanotide in Hypothalamic Obesity

Enzalutamide in First Line Androgen Deprivation Therapy for Metastatic Prostate Cancer